Researchers have created tiny DNA nanorobots that can deliver a protein payload that cuts off the blood supply to tumors in mice.

DNA Origami

According to a new study, the research team was able to create DNA nanorobots that can travel through the bloodstream, locate tumors, and deliver a protein that induces blood clotting, thus blocking the supply of blood to these tumors and causing them to die.

The researchers began by creating a self-assembling, rectangular DNA-origami sheet. They then linked thrombin, one of the enzymes responsible for blood clotting, to this sheet. Next, they formed the sheet into a tube and pinned it using DNA fasteners to join the edges; this resulted in a tubular nanorobot carrying a payload of thrombin within.

Perhaps the most impressive was how they designed the DNA fasteners, which were made to disconnect when encountering nucleolin, a protein unique to the surface of tumor blood vessel cells. Once this happens, the tube pops open and delivers the blood-clotting payload to the blood vessel of the tumor.

Cutting off the blood supply

Finally, the researchers injected these nanorobots into mice with human breast cancer tumors. As hoped, when the nanorobots encountered tumor blood vessel cells, they deployed their payloads and caused extensive blood clots within a 48-hour period. Even better, they caused no blood clotting elsewhere in the mice, so they were only reacting to tumor blood vessel cells as planned.

The blood clots caused necrosis in the tumors as they were starved of blood and the nutrients it carries. The result was that the treated mice had a higher survival rate than the control mice. They also found similarly increased survival in a mouse model of melanoma and in mice with xenografts of human ovarian cancer cells.

They also tested the therapy on micro pigs to see if any clotting was caused; none was observed, which is good news for potential translation of the technique to humans.


More studies are needed to ensure that there are no unwanted side effects, such as clotting elsewhere or immune responses created by this technique. However, taking this therapy from mice to humans will be a hugely challenging step, as it is not yet clear that targeting nucleolin to deliver thrombin will be effective in humans.

That said, the study is certainly a breakthrough because this technique serves as a platform that could potentially be used to deliver other useful proteins to target cells. It is not hard, for example, to see their potential for delivering an apoptosis-inducing protein to senescent cells if a suitable and unique surface marker can be identified on those cells.


[1] Zhang, Q., Jiang, Q., Li, N., Dai, L., Liu, Q., Song, L., … & Du, Y. (2014). DNA origami as an in vivo drug delivery vehicle for cancer therapy. Acs Nano, 8(7), 6633-6643.

CategoryNews, Research
About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
Write a comment:


Your email address will not be published.

Privacy Policy / Terms Of Use

       Powered by MMD